Alzheimer Disease (MMSE 15-23 and CDR1 or 2)
Showing 1 - 25 of >10,000
Alzheimer, Alzheimer 1, Alzheimer 2 Trial in United States (Sensory Stimulation System (GS120) - Active, Sensory Stimulation
Recruiting
- Alzheimer Disease
- +34 more
- Sensory Stimulation System (GS120) - Active
- Sensory Stimulation System (GS120) - Sham
-
Washington, District of Columbia
- +24 more
Jan 27, 2023
Alzheimer's Disease, Dementia Trial in Toronto, Riga (drug, genetic, other, behavioral)
Active, not recruiting
- Alzheimer's Disease
- Dementia
- Spinal anesthesia group: bupivacaine 10-15mg
- +4 more
-
Toronto, Ontario, Canada
- +2 more
May 31, 2021
Alzheimer, Alzheimer 1, Alzheimer 2 Trial in Ventura (No Intervention)
Recruiting
- Alzheimer Disease
- +22 more
- No Intervention
-
Ventura, CaliforniaProgenaBiome
Sep 2, 2021
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
Mild Cognitive Impairment, Mild Dementia, Fasting-Mimicking Diet Trial in Genoa, Genova, Perugia (Fasting-Mimicking Diet
Recruiting
- Mild Cognitive Impairment
- +2 more
- Fasting-Mimicking Diet ProlonADTM
-
Genoa, GE, Italy
- +2 more
Jul 27, 2022
Alzheimer's Disease Trial in Worldwide (Placebo, Gantenerumab)
Alzheimer Trial in Worldwide (LY3372689, Placebo)
Active, not recruiting
- Alzheimer Disease
- LY3372689
- Placebo
-
Canoga Park, California
- +70 more
Jan 18, 2023
Alzheimer's Disease Trial in Worldwide (Gantenerumab, Placebo)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial Trial in Worldwide (Gantenerumab, Solanezumab, Matching Placebo
Alzheimer's Disease Trial in Worldwide (Semorinemab, Placebo, [18F]GTP1)
Active, not recruiting
- Alzheimer's Disease
- Semorinemab
- +2 more
-
Garden Grove, California
- +48 more
Sep 1, 2022
Alzheimer's Disease, Dementia, Brain Diseases Trial in Daejeon, Busan, Seoul (ATNC MDD-V1 (Real TMS + Real Cog), ATNC MDD-V1
Recruiting
- Alzheimer's Disease
- +7 more
- ATNC MDD-V1 (Real TMS + Real Cog)
- ATNC MDD-V1 (Sham TMS + Real Cog)
-
Daejeon, Jung-gu, Korea, Republic of
- +2 more
Oct 11, 2023
Cognitive Disorders Trial (Blood samples, Interviewing the subject and scales, Neurocognitive evaluation)
Not yet recruiting
- Cognitive Disorders
- Blood samples
- +5 more
- (no location specified)
May 25, 2023
Alzheimer 3, Epilepsy Trial in Changsha (Lacosamide 100 mg, Levetiracetam 250mg)
Recruiting
- Alzheimer Disease 3
- Epilepsy
- Lacosamide 100 mg
- Levetiracetam 250mg
-
Changsha, Hunan, ChinaXiangya Hospital of Central South University
Aug 2, 2023
Alzheimer Trial in Ramat Gan (SCI -110)
Recruiting
- Alzheimer Disease
- SCI -110
-
Ramat Gan, IsraelThe Israeli Medical Center for Alzheimer's
Feb 3, 2022
Cognitive Health in Ageing Register: Investigational,
Active, not recruiting
- Alzheimer's Disease
- Plaque, Amyloid
-
Edinburgh, United Kingdom
- +1 more
Jan 31, 2023
Alzheimer (AD) Trial in Canada, Japan, United States (LY3303560, Placebo)
Alzheimer Trial in Santa Monica (NE3107)
Completed
- Alzheimer Disease
-
Santa Monica, CaliforniaNeurological Associates - The Interventional Group
Sep 26, 2022
Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy
Recruiting
- Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency
- +51 more
-
Lakewood, CaliforniaCongenital Muscle Disease International Registry (www.cmdir.org)
Aug 3, 2021
To Evaluate the Possible Benefit of Astaxanthin on Alzheimer Trial in Kaohsiung (Astaxanthin, Placebo)
Active, not recruiting
- To Evaluate the Possible Benefit of Astaxanthin on Alzheimer Disease
- Astaxanthin
- Placebo
-
Kaohsiung, TaiwanKaohsiung Medical University Chung-Ho Memorial Hospital
Aug 15, 2022
Tau Networks in Psychotic Alzheimer's Disease
Recruiting
- Alzheimer Disease
- +2 more
- [18F]-PI2620 PET scan
-
Manhasset, New YorkThe Feinstein Institutes for Medical Research
Apr 26, 2023
Moderate to Severe COPD (COPD) Trial in Worldwide (CHF1535 + CHF5992 dose 1 BID, CHF1535 + CHF5992 dose2 BID, CHF1535 daily
Completed
- Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- CHF1535 + CHF5992 dose 1 BID
- +2 more
-
Sofia, Bulgaria
- +5 more
Oct 28, 2021
Alzheimer's Disease Trial in Worldwide (Aducanumab (BIIB037), Placebo)
Terminated
- Alzheimer's Disease
- Aducanumab (BIIB037)
- Placebo
-
Phoenix, Arizona
- +180 more
Aug 9, 2021
Transcranial Random Noise, Electroencephalography, Alzheimer Trial in Hefei (High frequency transcranial random noise, Sham high
Recruiting
- Transcranial Random Noise
- +2 more
- High frequency transcranial random noise
- Sham high frequency transcranial random noise
-
Hefei, Anhui, ChinaAnhui Medical University
Jun 3, 2023
Alzheimer Trial (RB-ADSC)
Not yet recruiting
- Alzheimer Disease
- RB-ADSC
- (no location specified)
Dec 19, 2022